Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ngm Biopharmaceuticals Inc.
Headquarters: South San Francisco, CA, United States of America
Website: https://www.ngmbio.com/
Year Founded: 2008
Status: Private
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | May 16, 2024
Deals
With Proteologix takeout, J&J adds bispecifics for atopic dermatitis, asthma
Lead compound targeting IL-13 and TSLP trails bispecific competitors; second program set to advance behind it
BioCentury | Feb 27, 2024
Deals
Deals report: Novo-Neomorph seek degraders, Column Group taking NGM private, and more
Plus: agreements between Rigel-Blueprint, BeiGene-Shoreline and AstraZeneca-FibroGen
BioCentury | Feb 2, 2024
Finance
VC roundup: New funds for TCG and Seroba, rounds for Cour and Aqemia
Plus fresh cash for Halia and Neophore, and a new spinout from venture-backed Cumulus Oncology
BioCentury | May 5, 2023
Product Development
May 5 Quick Takes: Argenx’s Vyvgart tops 1Q23 consensus sales
Plus: Protalix/Chiesi therapy for Fabry wins EU approval, and updates from FibroGen, NGM and more
BioCentury | Apr 6, 2023
Management Tracks
After leading CinCor to exit, de Garidel finds next CEO role at Abivax
Plus: INKEF’s Bulthuis joins Syncona and updates from Rocket, NGM, SparingVision, Walden and more
BioCentury | Jan 4, 2023
Emerging Company Profile
Versant-backed Belharra: light-based chemoproteomics for all amino acids
Scripps spinout launches with $50M series A, $80M up front deal with Genentech to chase difficult targets
BioCentury | Dec 22, 2022
Regulation
Dec. 21 Quick Takes: Cash for NASH as Madrigal and Terns raise funds
Plus: FDA, EMA reviewing Pfizer’s etrasimod for ulcerative colitis and updates from ADC, AZ, CytoDyn, NGM-Merck and more
Items per page:
1 - 10 of 79